{"entity":{"id":"capecitabine-temozolomide","kind":"drug","name":"Capecitabine + temozolomide (CAPTEM)","aka":[],"tldr":"CAPTEM (capecitabine plus temozolomide) is an all-oral chemotherapy pair that shrinks pancreatic neuroendocrine tumours in about a third of patients.","summary":"ECOG-ACRIN E2211 (2018-2023): PFS 22.7 vs 14.4 months and higher response rate for CAPTEM versus temozolomide alone in pancreatic NETs; OS did not differ at final analysis. Used when tumour shrinkage is needed (bulky or symptomatic disease) and in grade 3 NETs. MGMT deficiency may predict response.","status":"established","asOf":"2026-09-07","links":[{"label":"ClinicalTrials.gov NCT01824875: ECOG-ACRIN E2211, temozolomide with or without capecitabine in advanced pancreatic neuroendocrine tumours (phase 2)","url":"https://clinicaltrials.gov/study/NCT01824875"}],"tags":[],"related":[],"cancers":["neuroendocrine","pancreatic-net","grade-3-net"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["temozolomide"],"companies":["ecog-acrin"],"institutions":[],"pathways":[],"terms":["mgmt"],"trials":["nct04919226"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"Oral cytotoxic regimen","mechanism":"Fluoropyrimidine plus alkylating agent; capecitabine depletes MGMT, sensitising to temozolomide.","approvals":[],"mechanismSteps":[],"dosing":{"route":"Oral","schedule":"Capecitabine 750 mg/m² twice daily days 1-14, temozolomide 200 mg/m² days 10-14, every 28 days","monitoring":"Blood counts, hand-foot syndrome"},"toxicity":[{"event":"Neutropenia (grade 3-4)","grade3PlusPct":13,"note":"E2211"},{"event":"Thrombocytopenia (grade 3-4)","grade3PlusPct":15},{"event":"Fatigue","anyGradePct":50}],"access":[],"regulatoryEvents":[]},"route":"/drugs/capecitabine-temozolomide/","neighbours":{"cancer":[{"id":"extrapulmonary-nec","kind":"cancer","name":"Extrapulmonary neuroendocrine carcinoma","route":"/cancers/extrapulmonary-nec/"},{"id":"grade-3-net","kind":"cancer","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/cancers/grade-3-net/"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"pancreatic-net","kind":"cancer","name":"Pancreatic neuroendocrine tumours","route":"/cancers/pancreatic-net/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"term":[{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/"}],"trial":[{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/"}],"idea":[{"id":"idea-bio2-lean-mass-dosing","kind":"idea","name":"Dose chemotherapy by muscle mass, not body surface area","route":"/ideas/idea-bio2-lean-mass-dosing/"}]}}